Highlighting the use of micro and nanoparticles based-drug delivery systems for the treatment of Helicobacter pylori infections

References

• Amin M, Anwar F, Janjua MRSA, Iqbal MA, Rashid U. 2012. Green synthesis of silver nanoparticles through reduction with Solanum xanthocarpum L. berry extract: characterization, antimicrobial and urease inhibitory activities against Helicobacter pylori. Int J Mol Sci. 13(8):9923–9941.
   PubMed Web of Science ®Google Scholar
• Abadi ATB. 2017. Strategies used by Helicobacter pylori to establish persistent infection. World J Gastroenterol. 23(16):2870–2882.
   PubMed Web of Science ®Google Scholar
• Adamsson I, Edlund C, Nord CE. 2000. Microbial ecology and treatment of Helicobacter pylori infections: review. J Chemother. 12(1):5–16.
   PubMed Web of Science ®Google Scholar
• Adebisi AO, Conway BR. 2015. Modification of drug delivery to improve antibiotic targeting to the stomach. Ther Deliv. 6(6):741–762.
   PubMed Web of Science ®Google Scholar
• Ahmad T, Wani IA, Lone IH, Ganguly A, Manzoor N, Ahmad A, Ahmed J, Al-Shihri AS. 2013. Antifungal activity of gold nanoparticles prepared by solvothermal method. Mater Res Bull. 48(1):12–20.
   Web of Science ®Google Scholar
• Alam MI, Paget T, Elkordy AA. 2016. Characterization of furazolidone-chitosan based spray dried microparticles regarding their drug release and mucin adsorptive properties. Powder Technol. 295:175–179.
   Web of Science ®Google Scholar
• Ali MS, Pandit V, Jain M, Dhar KL. 2014. Mucoadhesive microparticulate drug delivery system of curcumin against Helicobacter pylori infection: design, development and optimization. J Adv Pharm Technol Res. 5(1):48–56.
   PubMedGoogle Scholar
• Amin M, Hameed S, Ali A, Anwar F, Shahid SA, Shakir I, Yaqoob A, Hasan S, Khan SA. Others 2014. Green synthesis of silver nanoparticles: structural features and in vivo and in vitro therapeutic effects against Helicobacter pylori induced gastritis. Bioinorg Chem Appl. 2014;135824.
   PubMed Web of Science ®Google Scholar
• Andrews GP, Laverty TP, Jones DS. 2009. Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm. 71(3):505–518.
   PubMed Web of Science ®Google Scholar
• Angsantikul P, Thamphiwatana S, Zhang Q, Spiekermann K, Zhuang J, Fang RH, Gao W, Obonyo M, Zhang L. 2018. Coating nanoparticles with gastric epithelial cell membrane for targeted antibiotic delivery against Helicobacter pylori infection. Adv Therap. 1(2):1800016.
   Google Scholar
• Ansari S, Yamaoka Y. 2019. Helicobacter pylori virulence factors exploiting gastric colonization and its pathogenicity. Toxins (Basel). 11(11):677.
   PubMed Web of Science ®Google Scholar
• Araujo VHS, da Silva PB, Szlachetka IO, da Silva SW, Fonseca-Santos B, Chorilli M, Ganassin R, de Oliveira GRT, da Rocha MCO, Fernandes RP, et al. 2020. The influence of NLC composition on curcumin loading under a physicochemical perspective and in vitro evaluation. Colloids Surfaces A Physicochem Eng Asp. 602:125070.
   Web of Science ®Google Scholar
• Arif M, Dong Q-J, Raja MA, Zeenat S, Chi Z, Liu C-G. 2018. Development of novel pH-sensitive thiolated chitosan/PMLA nanoparticles for amoxicillin delivery to treat Helicobacter pylori. Mater Sci Eng C Mater Biol Appl. 83:17–24.
   PubMed Web of Science ®Google Scholar
• Arora S, Bisen G, Budhiraja R. 2012. Mucoadhesive and muco-penetrating delivery systems for eradication of Helicobacter pylori. Asian J Pharm. 6(1):18.
   Google Scholar
• Arora S, Budhiraja RD. 2012. Chitosan-alginate microcapsules of amoxicillin for gastric stability and mucoadhesion. J Adv Pharm Technol Res. 3(1):68.
   PubMedGoogle Scholar
• Austin LA, Mackey MA, Dreaden EC, El-Sayed MA. 2014. The optical, photothermal, and facile surface chemical properties of gold and silver nanoparticles in biodiagnostics, therapy, and drug delivery. Arch Toxicol. 88(7):1391–1417.
   PubMed Web of Science ®Google Scholar
• Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. 2006. Gastroretentive dosage forms: Overview and special case of Helicobacter pylori. J Control Release. 111(1–2):1–18.
   PubMed Web of Science ®Google Scholar
• Benita S. 2005. Microencapsulation: methods and industrial applications. Boca Raton: CRC Press.
   Google Scholar
• Bizerra A, Silva V. 2016. SISTEMAS DE LIBERAÇÃO CONTROLADA: Mecanismos e aplicações. Rev Saúde e Meio Ambient – RESMA. 3:1–12.
   Google Scholar
• Bozzuto G, Molinari A. 2015. Liposomes as nanomedical devices. Int J Nanomed. 10:975–999.
   PubMed Web of Science ®Google Scholar
• Brust M, Walker M, Bethell D, Schiffrin DJ, Whyman R. 1994. Synthesis of thiol-derivatised gold nanoparticles in a two-phase liquid–liquid system. J Chem Soc Chem Commun. 0(7):801–802.
   Google Scholar
• Caban S, Aytekin E, Sahin A, Capan Y. 2014. Nanosystems for drug delivery. OA Drug Des Deliv. 2:2.
   Google Scholar
• Calixto G, Bernegossi J, de Freitas L, Fontana C, Chorilli M. 2016. Nanotechnology-based drug delivery systems for photodynamic therapy of cancer: a review. Molecules. 21(3):342.
   PubMed Web of Science ®Google Scholar
• Camargo BAF, Larissa S, De Souza MPC, Ramos M d S, Fortunato GC, Chorilli M, Bauab TM. 2020. General characteristics, main virulence markers and new approaches in the control of Helicobacter pylori. In: Curr A, editor. Helicobacter pylori from diagnosis to treat [Internet]. New York; p. 207. https://novapublishers.com/shop/helicobacter-pylori-from-diagnosis-to-treatment/
   Google Scholar
• Camargo BAF, Eduarda SSD, Noronha da SA, Leite CD, Renata Machado Ribeiro T, Júlia Mieli M, Borges Teixeira Zanatta M, Bento da Silva P, Rogerio Pavan F, Gallina Moreira C, et al. 2020. A new silver (I) coordination compound loaded into polymeric nanoparticles as a strategy to improve in vitro anti-Helicobacter pylori activity. Mol Pharm. 17:2287–2298.
   PubMedGoogle Scholar
• Carita AC, Eloy JO, Chorilli M, Lee RJ, Leonardi GR. 2017. Recent advances and perspectives in liposomes for cutaneous drug delivery. Curr Med Chem. 25:606–635.
   Google Scholar
• Carron MA, Tran VR, Sugawa C, Coticchia JM. 2006. Identification of Helicobacter pylori biofilms in human gastric mucosa. J Gastrointest Surg. 10(5):712–717.
   PubMed Web of Science ®Google Scholar
• Carvalho VFM, Salata GC, de Matos JKR, Costa-Fernandez S, Chorilli M, Steiner AA, de Araujo GLB, Silveira ER, Costa-Lotufo LV, Lopes LB. 2019. Optimization of composition and obtainment parameters of biocompatible nanoemulsions intended for intraductal administration of piplartine (piperlongumine) and mammary tissue targeting. Int J Pharm. 567:118460.
   PubMed Web of Science ®Google Scholar
• Castillo-Rojas G, Cerbón MA, López-Vidal Y. 2008. Presence of Helicobacter pylori in a Mexican pre-Columbian mummy. BMC Microbiol. 8(1):119.
   PubMedGoogle Scholar
• Cellini L, Grande R, Di Campli E, Traini T, Giulio M, Di Lannutti SN, Lattanzio R. 2008. Dynamic colonization of Helicobacter pylori in human gastric mucosa. Scand J Gastroenterol. 43(2):178–185.
   PubMed Web of Science ®Google Scholar
• Chakraborti S, Bhattacharya S, Chowdhury R, Chakrabarti P. 2013. The molecular basis of inactivation of metronidazole-resistant Helicobacter pylori using polyethyleneimine functionalized zinc oxide nanoparticles. PLoS One. 8(8):e70776.
   PubMed Web of Science ®Google Scholar
• Chang WL, Yeh YC, Sheu BS. 2018. The impacts of H. pylori virulence factors on the development of gastroduodenal diseases. J Biomed Sci. 25(1):1–9.
   PubMedGoogle Scholar
• Chauhan N, Tay ACY, Marshall BJ, Jain U. 2019. Helicobacter pylori VacA, a distinct toxin exerts diverse functionalities in numerous cells: an overview. Helicobacter. 24(1):e12544.
   PubMed Web of Science ®Google Scholar
• Chen Y, Blaser MJ. 2008. Helicobacter pylori colonization is inversely associated with childhood asthma. J Infect Dis. 198(4):553–560.
   PubMed Web of Science ®Google Scholar
• Choi H, Lee DG. 2015. Lycopene induces apoptosis in Candida albicans through reactive oxygen species production and mitochondrial dysfunction. Biochimie. 115:108–115.
   PubMed Web of Science ®Google Scholar
• Choi J, Joo YJ, Joon SK, Hwa YP, Yon HC, Kyung MK. 2006. Efficacy of two triple eradication regimens in children with Helicobacter pylori infection. J Korean Med Sci. 21(6):1037–1040.
   PubMed Web of Science ®Google Scholar
• Chorilli M, Calixto G, Rimério TC, Scarpa MV. 2013. Caffeine encapsulated in small unilamellar liposomes: characerization and in vitro release profile. J Dispers Sci Technol. 34:1465–1470.
   Web of Science ®Google Scholar
• Choudhury H, Gorain B, Pandey M, Khurana RK, Kesharwani P. 2019. Strategizing biodegradable polymeric nanoparticles to cross the biological barriers for cancer targeting. Int J Pharm. 565(February):509–522.
   PubMedGoogle Scholar
• Chung JG, Wu LT, Chang SH, Lo HH, Hsieh SE, Li YC, Hung CF. 1999. Inhibitory actions of berberine on growth and arylamine N -acetyltransferase activity in strains of Helicobacter pylori from peptic ulcer patients. Int J Toxicol. 18(1):35–40.
   Web of Science ®Google Scholar
• Clarke GM, Newton JM, Short MD. 1993. Gastrointestinal transit of pellets of differing size and density. Int J Pharm. 100(1–3):81–92.
   Google Scholar
• Coelho E, Magalhães A, Dinis-Ribeiro M, Reis CA. 2016. Mecanismos Moleculares de Adesão e Colonização da Mucosa Gástrica pela Helicobacter pylori e suas Implicações Clínicas Molecular Mechanisms for Adhesion and Colonization of Human Gastric Mucosa by Helicobacter pylori and its Clinical Implications. Acta Med Port. 29(7–8):476–483.
   PubMed Web of Science ®Google Scholar
• Conway BR. 2005. Drug delivery strategies for the treatment of Helicobacter pylori infections. Curr Pharm Des. 11(6):775–790.
   PubMed Web of Science ®Google Scholar
• Couvreur P, Puisieux F. 1993. Nano- and microparticles for the delivery of polypeptides and proteins. Adv Drug Deliv Rev. 10(2–3):141–162.
   Web of Science ®Google Scholar
• Cover TL, Tummuru MKR, Cao P, Thompson SA, Blaser MJ. 1994. Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori strains. J Biol Chem. 269(14):10566–10573.
   PubMed Web of Science ®Google Scholar
• Cover TL. 2016. Helicobacter pylori diversity and gastric cancer risk. MBio. 7(1):1–9.
   Web of Science ®Google Scholar
• da Silva PB, Machado RTA, Pironi AM, Alves RC, de Araújo PR, Dragalzew AC, Dalberto I, Chorilli M. 2019. Recent advances in the use of metallic nanoparticles with antitumoral action-review. Curr Med Chem. 26:2108–2146.
   PubMed Web of Science ®Google Scholar
• De Brito BB, Da Silva FAF, Soares AS, Pereira VA, Cordeiro Santos ML, Sampaio MM, Moreira Neves PH, De Melo FF. 2019. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol. 25:5578–5589.
   PubMed Web of Science ®Google Scholar
• de Freitas LM, Calixto GMF, Chorilli M, Giusti JSM, Bagnato VS, Soukos NS, Amiji MM, Fontana CR. 2016. Polymeric nanoparticle-based photodynamic therapy for chronic periodontitis in Vivo. Int J Mol Sci. 17:769.
   Web of Science ®Google Scholar
• de Souza MPC, Sábio RM, de Cássia Ribeiro T, dos Santos AM, Meneguin AB, Chorilli M. 2020. Highlighting the impact of chitosan on the development of gastroretentive drug delivery systems. Int J Biol Macromol. 159:804–822.
   PubMed Web of Science ®Google Scholar
• de Toledo LDAS, Rosseto HC, Bruschi ML. 2018. Iron oxide magnetic nanoparticles as antimicrobials for therapeutics. Pharm Dev Technol. 23(4):316–323.
   PubMed Web of Science ®Google Scholar
• Dizaj SM, Lotfipour F, Barzegar-Jalali M, Zarrintan MH, Adibkia K. 2014. Antimicrobial activity of the metals and metal oxide nanoparticles. Mater Sci Eng C Mater Biol Appl. 44:278–284.
   PubMed Web of Science ®Google Scholar
• Donbrow M. 1991. Microcapsules and nanoparticles in medicine and pharmacy. Boca Raton: CRC Press.
   Google Scholar
• dos Santos Ramos MA, Da Silva PB, De Toledo LG, Oda FB, Da Silva IC, dos Santos LC, dos Santos AG, De Almeida MTG, Pavan FR, Chorilli M, et al. 2019. Intravaginal delivery of Syngonanthus nitens (Bong.) Ruhland fraction based on a nanoemulsion system applied to vulvovaginal candidiasis treatment. J Biomed Nanotechnol. 15(5):1072–1089.
   PubMed Web of Science ®Google Scholar
• Dos Santos Ramos MA, Da Silva PB, Spósito L, De Toledo LG, Bonifácio B Vidal, Rodero CF, Dos Santos KC, Chorilli M, Bauab TM. 2018. Nanotechnology-based drug delivery systems for control of microbial biofilms: a review. Int J Nanomedicine. 13:1179–1213.
   PubMed Web of Science ®Google Scholar
• dos Santos Ramos MA, dos Santos KC, da Silva PB, de Toledo LG, Marena GD, Rodero CF, de Camargo BAF, Fortunato GC, Bauab TM, Chorilli M. 2020. Nanotechnological strategies for systemic microbial infections treatment: a review. Int J Pharm. 589:119780.
   PubMedGoogle Scholar
• Dziezak JD. 1988. Microencapsulation and encapsulated ingredients. Food Technol. 42(4):136–153.
   Web of Science ®Google Scholar
• El Nashar NF, Donia AA, Mady OY, El Maghraby GM. 2017. Formulation of clarithromycin floating microspheres for eradication of Helicobacter pylori. J Drug Deliv Sci Technol. 41:213–221.
   Web of Science ®Google Scholar
• Eloy JO, Ruiz A, de Lima FT, Petrilli R, Raspantini G, Nogueira KAB, Santos E, de Oliveira CS, Borges JC, Marchetti JM. 2020. EGFR-targeted immunoliposomes efficiently deliver docetaxel to prostate cancer cells. Colloids Surf B Biointerfaces. 194:111185.
   PubMed Web of Science ®Google Scholar
• Fachinetti N, Rigon RB, Eloy JO, Sato MR, dos Santos KC, Chorilli M. 2018. Comparative study of glyceryl behenate or polyoxyethylene 40 stearate-based lipid carriers for trans-resveratrol delivery: development, characterization and evaluation of the in vitro tyrosinase inhibition. AAPS PharmSciTech. 19(3):1401–1409.
   PubMed Web of Science ®Google Scholar
• Falush D, Wirth T, Linz B, Pritchard JK, Stephens M, Kidd M, Blaser MJ, Graham DY, Vacher S, Perez-Perez GI, et al. 2003. Traces of human migrations in Helicobacter pylori populations. Science (80-). 299(5612):1582–1585.
   PubMed Web of Science ®Google Scholar
• Faraday M. 1857. X. The Bakerian Lecture.—experimental relations of gold (and other metals) to light. Philos Trans R Soc Lond. 147:145–181.
   Google Scholar
• Ferreira RM, Machado JC, Letley D, Atherton JC, Pardo ML, Gonzalez CA, Carneiro F, Figueiredo C. 2012. A novel method for genotyping the Helicobacter pylori vacA intermediate region directly in gastric biopsy specimens. J Clin Microbiol. 50(12):3983–3989.
   PubMed Web of Science ®Google Scholar
• Fiorentino M, Ding H, Blanchard TG, Czinn SJ, Sztein MB, Fasano A. 2013. Helicobacter pylori-induced disruption of monolayer permeability and proinflammatory cytokine secretion in polarized human gastric epithelial cells. Infect Immun. 81(3):876–883.
   PubMed Web of Science ®Google Scholar
• Foegeding NJ, Raghunathan K, Campbell AM, Kim SW, Lau KS, Kenworthy AK, Cover TL, Ohi MD. 2019. Intracellular degradation of Helicobacter pylori VacA toxin as a determinant of gastric epithelial cell viability. Infect Immun. 87(4):e00783-18.
   PubMed Web of Science ®Google Scholar
• Garg T, Kumar A, Rath G, Goyal AK. 2014. Gastroretentive drug delivery systems for therapeutic management of peptic ulcer. Crit Rev Ther Drug Carr Syst. 31(6):531–557.
   PubMed Web of Science ®Google Scholar
• Gatti THH, Eloy JO, Ferreira LMB, Da SI, Pavan FR, Gremião MPD, Chorilli M. 2018. Insulin-loaded polymeric mucoadhesive nanoparticles: development, characterization and cytotoxicity evaluation. Brazilian J Pharm Sci. 54(1):e17314.
   Web of Science ®Google Scholar
• Geilich BM, Gelfat I, Sridhar S, van de Ven AL, Webster TJ. 2017. Superparamagnetic iron oxide-encapsulating polymersome nanocarriers for biofilm eradication. Biomaterials. 119:78–85.
   PubMed Web of Science ®Google Scholar
• Ghayour N, Hosseini SMH, Eskandari MH, Esteghlal S, Nekoei A-R, Gahruie HH, Tatar M, Naghibalhossaini F. 2019. Nanoencapsulation of quercetin and curcumin in casein-based delivery systems. Food Hydrocoll. 87:394–403.
   Web of Science ®Google Scholar
• Ghosh P, Han G, De M, Kim CK, Rotello VM. 2008. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev. 60(11):1307–1315.
   PubMed Web of Science ®Google Scholar
• Gopinath V, Priyadarshini S, MubarakAli D, Loke MF, Thajuddin N, Alharbi NS, Yadavalli T, Alagiri M, Vadivelu J. 2019. Anti-Helicobacter pylori, cytotoxicity and catalytic activity of biosynthesized gold nanoparticles: multifaceted application. Arab J Chem. 12(1):33–40.
   Web of Science ®Google Scholar
• Gordillo-Galeano A, Mora-Huertas CE. 2018. Solid lipid nanoparticles and nanostructured lipid carriers: A review emphasizing on particle structure and drug release. Eur J Pharm Biopharm. 133(August):285–308.
   PubMedGoogle Scholar
• Graham DY, Klein PD. 1991. What you should know about the methods, problems, interpretations, and uses of urea breath tests. Am J Gastroenterol. 86(9):1118–1122.
   PubMed Web of Science ®Google Scholar
• Graham DY, Lu H, Yamaoka Y. 2007. A report card to grade Helicobacter pylori therapy. Helicobacter. 12(4):275–278.
   PubMed Web of Science ®Google Scholar
• Grzeszczuk MJ, Bocian-Ostrzycka KM, Banaś AM, Roszczenko-Jasinska P, Malinowska A, Stralova H, Haas R, Meyer TF, Jagusztyn-Krynicka EK. 2018. Thioloxidoreductase HP0231 of Helicobacter pylori impacts HopQ-dependent CagA translocation. Int J Med Microbiol. 308(8):977–985.
   PubMed Web of Science ®Google Scholar
• Guan J, Zhou L, Nie S, Yan T, Tang X, Pan W. 2010. A novel gastric-resident osmotic pump tablet: In vitro and in vivo evaluation. Int J Pharm. 383(1–2):30–36.
   PubMed Web of Science ®Google Scholar
• Gupta R, Tripathi P, Bhardwaj P, Maho A. 2018. Recent advances in gastro retentive drug delivery systems and its application on treatment of H. pylori infections. J Anal Pharm Res. 7(4):404–410.
   Google Scholar
• Gurunathan S, Jeong J-K, Han JW, Zhang X-F, Park JH, Kim J-H. 2015. Multidimensional effects of biologically synthesized silver nanoparticles in Helicobacter pylori, Helicobacter felis, and human lung (L132) and lung carcinoma A549 cells. Nanoscale Res Lett. 10(1):1–17.
   PubMedGoogle Scholar
• Hao S, Wang Y, Wang B. 2014. Sinking-magnetic microparticles prepared by the electrospray method for enhanced gastric antimicrobial delivery. Mol Pharm. 11(5):1640–1650.
   PubMedGoogle Scholar
• Hardenia A, Gupta A, Kumar Singh RP. 2016. In vitro and in vivo evaluation of mucoadhesive microspheres for treatment of Helicobacter pylori and its associated diseases. Asian J Pharm Free Full Text Artic from Asian J Pharm. 10(03).
   Google Scholar
• Henriques PC, Costa LM, Seabra CL, Antunes B, Silva-Carvalho R, Junqueira-Neto S, Maia AF, Oliveira P, Magalhães A, Reis CA, et al. 2020. Orally administrated chitosan microspheres bind Helicobacter pylori and decrease gastric infection in mice. Acta Biomater. 114:206–220.
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. 2011. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA. 108(27):10980–10985.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhu Y, Lu NH. 2017. Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance. Front Cell Infect Microbiol. 7(MAY):1–20.
   PubMedGoogle Scholar
• Ibelli T, Templeton S, Levi-Polyachenko N. 2018. Progress on utilizing hyperthermia for mitigating bacterial infections. Int J Hyperthermia. 34(2):144–156.
   PubMed Web of Science ®Google Scholar
• Imkamp F, Lauener FN, Pohl D, Lehours P, Vale FF, Jehanne Q, Zbinden R, Keller PM, Wagner K. 2019. Rapid characterization of virulence determinants in Helicobacter pylori isolated from non-atrophic gastritis patients by next-generation sequencing. J Clin Med. 8(7):1030.
   Web of Science ®Google Scholar
• Javadzadeh Y, Hamedeyaz S. 2014. Floating drug delivery systems for eradication of Helicobacter pylori in treatment of peptic ulcer disease. In: Trends in Helicobacter pylori infection. InTech; p. 31–80.
   Google Scholar
• Javaheri A, Kruse T, Moonens K, Mejías-Luque R, Debraekeleer A, Asche CI, Tegtmeyer N, Kalali B, Bach NC, Sieber SA. 2016. Helicobacter pylori adhesin HopQ engages in a virulence-enhancing interaction with human CEACAMs. Nat Microbiol. 2(1):1–12.
   Web of Science ®Google Scholar
• Jing ZW, Jia YY, Wan N, Luo M, Huan ML, Kang T Bin, Zhou SY, Zhang BL. 2016. Design and evaluation of novel pH-sensitive ureido-conjugated chitosan/TPP nanoparticles targeted to Helicobacter pylori. Biomaterials. 84:276–285.
   PubMed Web of Science ®Google Scholar
• Jung SW, Thamphiwatana S, Zhang L, Obonyo M. 2015. Mechanism of antibacterial activity of liposomal linolenic acid against helicobacter pylori. PLoS One. 10(3):e0116519.
   PubMed Web of Science ®Google Scholar
• Kabamba ET, Tuan VP, Yamaoka Y. 2018. Genetic populations and virulence factors of Helicobacter pylori. Infect Genet Evol. 60(February):109–116.
   PubMedGoogle Scholar
• Kamat PV. 2002. Photophysical, photochemical and photocatalytic aspects of metal nanoparticles. J Phys Chem B. 106:7729–7744.
   Web of Science ®Google Scholar
• Kao CY, Sheu BS, Wu JJ. 2016. Helicobacter pylori infection: an overview of bacterial virulence factors and pathogenesis. Biomed J. 39(1):14–23.
   PubMed Web of Science ®Google Scholar
• Kavitt RT, Lipowska AM, Anyane-Yeboa A, Gralnek IM. 2019. Diagnosis and treatment of peptic ulcer disease. Am J Med. 132(4):447–456.
   PubMed Web of Science ®Google Scholar
• Khosa A, Reddi S, Saha RN. 2018. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother. 103(February):598–613.
   PubMedGoogle Scholar
• Khutoryanskiy VV. 2011. Advances in mucoadhesion and mucoadhesive polymers. Macromol Biosci. 11(6):748–764.
   PubMed Web of Science ®Google Scholar
• Kinloch AJ. 1980. The science of adhesion. J Mater Sci. 15(9):2141–2166.
   Web of Science ®Google Scholar
• Kumar M, Varshney L, Francis S. 2005. Radiolytic formation of Ag clusters in aqueous polyvinyl alcohol solution and hydrogel matrix. Radiat Phys Chem. 73(1):21–27.
   Web of Science ®Google Scholar
• Kumari A, Singla R, Guliani A, Yadav SK. 2014. Nanoencapsulation for drug delivery. Excli J. 13:265–286.
   PubMed Web of Science ®Google Scholar
• Kuo C-J, Chen C-W, Le P-H, Hsu J-T, Lin C-Y, Cheng H-T, Su M-Y, Lin C-J, Chiu C-T. 2019. Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections. Therap Adv Gastroenterol. 12(6):1756284819870960..
   Google Scholar
• Ladeira MSP, Salvadori MDF, Rodrigues AMM. 2003. Biopatologia do Helicobacter pylori. J Bras Patol e Med Lab. 39:335–342.
   Google Scholar
• Lamichhane N, Udayakumar TS, D’Souza WD, Simone CB, Raghavan SR, Polf J, Mahmood J. 2018. Liposomes: clinical applications and potential for image-guided drug delivery. Molecules. 23(2):288–217.
   PubMed Web of Science ®Google Scholar
• Lee DW, Hwang SJ, Park JB, Park HJ. 2003. Preparation and release characteristics of polymer-coated and blended alginate microspheres. J Microencapsul. 20(2):179–192.
   PubMed Web of Science ®Google Scholar
• Li M, Du C, Guo N, Teng Y, Meng X, Sun H, Li S, Yu P, Galons H. 2019. Composition design and medical application of liposomes. Eur J Med Chem. 164:640–653.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang W-P, Wang H-Y, Cho C-H. 2000. Intragastric administration of heparin enhances gastric ulcer healing through a nitric oxide-dependent mechanism in rats. Eur J Pharmacol. 399(2–3):205–214.
   PubMed Web of Science ®Google Scholar
• Lima LCD, Ramos MAS, Toledo LG, de Rodero CF, Hilário F, dos Santos LC, Chorilli M, Bauab TM. 2020. Syngonanthus nitens (Bong.) Ruhland derivatives loaded into a lipid nanoemulsion for enhanced antifungal activity against Candida parapsilosis. Curr Pharm Des. 26:1556–1565.
   PubMed Web of Science ®Google Scholar
• Lin T-C, Hung K-H, Peng C-H, Liu J-H, Woung L-C, Tsai C-Y, Chen S-J, Chen Y-T, Hsu C-C. 2015. Nanotechnology-based drug delivery treatments and specific targeting therapy for age-related macular degeneration. J Chin Med Assoc. 78(11):635–641.
   PubMed Web of Science ®Google Scholar
• Lin Y-H, Chiou S-F, Lai C-H, Tsai S-C, Chou C-W, Peng S-F, He Z-S. 2012. Formulation and evaluation of water-in-oil amoxicillin-loaded nanoemulsions using for Helicobacter pylori eradication. Process Biochem. 47(10):1469–1478.
   Web of Science ®Google Scholar
• Lin YH, Lin JH, Chou SC, Chang SJ, Chung CC, Chen YS, Chang CH. 2015. Berberine-loaded targeted nanoparticles as specific Helicobacter pylori eradication therapy: in vitro and in vivo study. Nanomedicine (Lond). 10(1):57–71.
   PubMed Web of Science ®Google Scholar
• Lin YH, Tsai SC, Lai CH, Lee CH, He ZS, Tseng GC. 2013. Genipin-cross-linked fucose-chitosan/heparin nanoparticles for the eradication of Helicobacter pylori. Biomaterials. 34(18):4466–4479.
   PubMed Web of Science ®Google Scholar
• Liu Y-L, Chen D, Shang P, Yin D-C. 2019. A review of magnet systems for targeted drug delivery. J Control Release. 302:90–104.
   PubMed Web of Science ®Google Scholar
• Logothetidis S. 2006. Nanotechnology in medicine: the medicine of tomorrow and nanomedicine. Hippokratia. 10(1):7–21.
   Google Scholar
• Lopes CM, Bettencourt C, Rossi A, Buttini F, Barata P. 2016. Overview on gastroretentive drug delivery systems for improving drug bioavailability. Int J Pharm. 510(1):144–158.
   PubMedGoogle Scholar
• Luk BT, Zhang L. 2015. Cell membrane-camouflaged nanoparticles for drug delivery. J Control Release. 220(Pt B):600–607.
   PubMed Web of Science ®Google Scholar
• Luo D, Guo J, Wang F, Sun J, Li G, Cheng X, Chang M, Yan X. 2009. Preparation and evaluation of anti-Helicobacter pylori efficacy of chitosan nanoparticles in vitro and in vivo. J Biomater Sci Polym Ed. 20(11):1587–1596.
   PubMed Web of Science ®Google Scholar
• Luo M, Jia YY, Jing ZW, Li C, Zhou SY, Mei QB, Zhang BL. 2018. Construction and optimization of pH-sensitive nanoparticle delivery system containing PLGA and UCCs-2 for targeted treatment of Helicobacter pylori. Colloids Surf B Biointerfaces. 164:11–19.
   PubMed Web of Science ®Google Scholar
• Mahady GB, Pendland SL, Stoia A, Chadwick LR. 2003. In vitro susceptibility of Helicobacter pylori to isoquinoline alkaloids from Sanguinaria canadensis and Hydrastis canadensis. Phytother Res. 17(3):217–221.
   PubMed Web of Science ®Google Scholar
• Mansuri S, Kesharwani P, Jain K, Tekade RK, Jain NK. 2016. Mucoadhesion: A promising approach in drug delivery system. REACT. 100:151–172.
   Web of Science ®Google Scholar
• Marshall B. 2016. A brief history of the discovery of Helicobacter pylori. In: Suzuki H, Warren R, Marshall B, editors. Helicobacter pylori. Tokyo: Springer.
   Google Scholar
• Martínez LE, Hardcastle JM, Wang J, Pincus Z, Tsang J, Hoover TR, Bansil R, Salama NR. 2016. Helicobacter pylori strains vary cell shape and flagellum number to maintain robust motility in viscous environments. Mol Microbiol. 99(1):88–110.
   PubMed Web of Science ®Google Scholar
• Mathur M, Devi VK. 2017. Potential of novel drug delivery systems in the management of topical candidiasis. J Drug Target. 25(8):685–703.
   PubMed Web of Science ®Google Scholar
• McClements DJ. 2018. Advances in nanoparticle and microparticle delivery systems for increasing the dispersibility, stability, and bioactivity of phytochemicals. Biotechnol Adv. 38:107287.
   PubMed Web of Science ®Google Scholar
• McNamara D, Buckley M, Gilvarry J, O’Morain C. 2002. Does Helicobacter pylori eradication affect symptoms in nonulcer dyspepsia: a 5-year follow-up study. Helicobacter. 7(5):317–321.
   PubMed Web of Science ®Google Scholar
• Megraud F, Trimoulet P, Lamouliatte H, Boyanova L. 1991. Bactericidal effect of amoxicillin on Helicobacter pylori in an in vitro model using epithelial cells. Antimicrob Agents Chemother. 35(5):869–872.
   PubMed Web of Science ®Google Scholar
• Melo MA Jr, Santos LSS, Gonçalves MDC, Nogueira AF. 2012. Preparação de nanopartículas de prata e ouro: um método simples para a introdução da nanociência em laboratório de ensino. Quim Nova. 35:1872–1878.
   Web of Science ®Google Scholar
• Mishra M. 2015. Handbook of encapsulation and controlled release. Boca Raton: CRC press.
   Google Scholar
• More MP, Ganguly PR, Pandey AP, Dandekar PP, Jain RD, Patil PO, Deshmukh PK. 2017. Development of surface engineered mesoporous alumina nanoparticles: drug release aspects and cytotoxicity assessment. IET Nanobiotechnol. 11(6):661–668.
   Web of Science ®Google Scholar
• Mudie DM, Amidon GL, Amidon GE. 2010. Physiological parameters for oral delivery and in vitro testing. Mol Pharm. 7(5):1388–1405.
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. 2002. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 242(1–2):121–128.
   PubMed Web of Science ®Google Scholar
• Nagahara N, Akiyama Y, Nakao M, Tada M, Kitano M, Ogawa Y. 1998. Mucoadhesive microspheres containing amoxicillin for clearance of Helicobacter pylori. Antimicrob Agents Chemother. 42(10):2492–2494.
   PubMed Web of Science ®Google Scholar
• Nallasamy V, Ramanathan S, Perumal P. 2013. In vivo evaluation of amoxicillin trihydrate and clarithromycin-loaded mucoadhesive microspheres for H. pylori eradication. Trop J Pharm Res. 12(2):143–147.
   Web of Science ®Google Scholar
• Narain A, Asawa S, Chhabria V, Patil-Sen Y. 2017. Cell membrane coated nanoparticles: next-generation therapeutics. Nanomedicine (Lond). 12(21):2677–2692.
   PubMed Web of Science ®Google Scholar
• Narayanan M, Reddy KM, Marsicano E. 2018. Peptic ulcer disease and Helicobacter pylori infecti. Sci Med. 115(3):219–224.
   Google Scholar
• Nayak AK, Malakar J, Sen KK. 2010. Gastroretentive drug delivery technologies: current approaches and future. J Pharm Educ Res. 1(2):1–10.
   Google Scholar
• Nejati S, Karkhah A, Darvish H, Validi M, Ebrahimpour S, Nouri HR. 2018. Influence of Helicobacter pylori virulence factors CagA and VacA on pathogenesis of gastrointestinal disorders. Microb Pathog. 117(January):43–48.
   PubMedGoogle Scholar
• Neouze MA, Schubert U. 2008. Surface modification and functionalization of metal and metal oxide nanoparticles by organic ligands. Monatsh Chem. 139(3):183–195.
   Web of Science ®Google Scholar
• Newman A. 2015. Pharmaceutical amorphous solid dispersions. New York: John Wiley & Sons.
   Google Scholar
• Ngwuluka NC, Choonara YE, Kumar P, Du TL, Modi G, Pillay V. 2015. An optimized gastroretentive nanosystem for the delivery of levodopa. Int J Pharm. 494:49–65.
   PubMedGoogle Scholar
• Nohemann L, Almeida MP de, Ferrari PC. 2017. Floating ability and drug release evaluation of gastroretentive microparticles system containing metronidazole obtained by spray drying. Braz J Pharm Sci. 53(1):e15218.
   Web of Science ®Google Scholar
• Odeku OA, Aderogba AA, Ajala TO, Akin-Ajani OD, Okunlola A. 2017. Formulation of floating metronidazole microspheres using cassava starch (Manihot esculenta) as polymer. J Pharm Investig. 47(5):445–451.
   Google Scholar
• Pakhale NV, Gondkar SB, Saudagar RB. 2019. Effervescent floating drug delivery system: a review. J Drug Deliv Ther. 9(3-s):836–838.
   Google Scholar
• Pan-In P, Banlunara W, Chaichanawongsaroj N, Wanichwecharungruang S. 2014. Ethyl cellulose nanoparticles: clarithomycin encapsulation and eradication of H. pylori. Carbohydr Polym. 109:22–27.
   PubMed Web of Science ®Google Scholar
• Pan-In P, Tachapruetinun A, Chaichanawongsaroj N, Banlunara W, Suksamrarn S, Wanichwecharungruang S. 2014. Combating Helicobacter pylori infections with mucoadhesive nanoparticles loaded with Garcinia mangostana extract. Nanomedicine (Lond). 9(3):457–468.
   PubMedGoogle Scholar
• Park C, Youn H, Kim H, Noh T, Kook YH, Oh ET, Park HJ, Kim C. 2009. Cyclodextrin-covered gold nanoparticles for targeted delivery of an anti-cancer drug. J Mater Chem. 19(16):2310–2315.
   Web of Science ®Google Scholar
• Park K, Robinson JR. 1984. Bioadhesive polymers as platforms for oral-controlled drug delivery: method to study bioadhesion. Int J Pharm. 19(2):107–127.
   Web of Science ®Google Scholar
• Patel J, Patil P. 2012. Preparation and characterization of amoxicillin mucoadhesive microparticles using solution-enhanced dispersion by supercritical CO2. J Microencapsul. 29(4):398–408.
   PubMed Web of Science ®Google Scholar
• Paul AD, Samatha P, Manasa S, Munemma R, Supriya D. 2017. Modeling the oral cavity with mucoadhesive drug delivery systems-a potential alternative to conventional therapy. Int J Pharm Sci Drug Res. 9(6):299–307.
   Google Scholar
• Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, Kulkarni GT. 2011. Gastroretentive dosage forms: a review with special emphasis on floating drug delivery systems. Drug Deliv. 18(2):97–110.
   PubMed Web of Science ®Google Scholar
• Proctor MJ, Deans C. 2014. Complications of peptic ulcers. Surgery. 32(11):599–607.
   Google Scholar
• Rai VK, Mishra N, Yadav KS, Yadav NP. 2018. Nanoemulsion as pharmaceutical carrier for dermal and transdermal drug delivery: formulation development, stability issues, basic considerations and applications. J Control Release. 270:203–225.
   Google Scholar
• Ramteke S, Ganesh N, Bhattacharya S, Jain NK. 2008. Triple therapy-based targeted nanoparticles for the treatment of Helicobacter pylori. J Drug Target. 16(9):694–705.
   PubMed Web of Science ®Google Scholar
• Safarov T, Kiran B, Bagirova M, Allahverdiyev AM, Abamor ES. 2019. An overview of nanotechnology-based treatment approaches against Helicobacter pylori. Expert Rev Anti Infect Ther. 17:829–840.
   PubMed Web of Science ®Google Scholar
• Sakima V, Barbugli P, Cerri P, Chorilli M, Carmello J, Pavarina A, Mima E. 2018. Antimicrobial photodynamic therapy mediated by curcumin-loaded polymeric nanoparticles in a murine model of oral candidiasis. Molecules. 23(8):2075.
   Web of Science ®Google Scholar
• Saravanakumar K, Chelliah R, MubarakAli D, Oh D-H, Kathiresan K, Wang M-H. 2019. Unveiling the potentials of biocompatible silver nanoparticles on human lung carcinoma A549 cells and Helicobacter pylori. Sci Rep. 9(1):1–8.
   PubMedGoogle Scholar
• Saravanan M, Gopinath V, Chaurasia MK, Syed A, Ameen F, Purushothaman N. 2018. Green synthesis of anisotropic zinc oxide nanoparticles with antibacterial and cytofriendly properties. Microb Pathog. 115:57–63.
   PubMed Web of Science ®Google Scholar
• Sarojini S, Manavalan R. 2012. An overview on various approaches to gastroretentive dosage forms. Int J Drug Dev Res. 4(1):1–13.
   Google Scholar
• Sato MR, Oshiro Junior Ja Machado RTA, de Souza PC, Campos DL, Pavan FR, da Silva PB, Chorilli M. 2017. Nanostructured lipid carriers for incorporation of copper(II) complexes to be used against Mycobacterium tuberculosis. Drug Des Devel Ther. 11:909–921.
   PubMed Web of Science ®Google Scholar
• Sato MR, Oshiro-Junior JA, Souza PC, Campos DL, Pereira-Da-Silva MA, Pavan FR, Silva Pb D, Chorilli M. 2019. Copper(II) complex-loaded castor oil-based nanostructured lipid carriers used against Mycobacterium tuberculosis: development, characterisation, in vitro and in vivo biological assays. Pharmazie.  74(12):715–720.
   Google Scholar
• Schreiber S, Konradt M, Groll C, Scheid P, Hanauer G, Werling HO, Josenhans C, Suerbaum S. 2004. The spatial orientation of Helicobacter pylori in the gastric mucus. Proc Natl Acad Sci USA. 101(14):5024–5029.
   PubMed Web of Science ®Google Scholar
• Seabra CL, Nunes C, Gomez-Lazaro M, Correia M, Machado JC, Gonçalves IC, Reis CA, Reis S, Martins MCL. 2017. Docosahexaenoic acid loaded lipid nanoparticles with bactericidal activity against Helicobacter pylori. Int J Pharm. 519(1–2):128–137.
   PubMed Web of Science ®Google Scholar
• Shaikh S, Nazam N, Rizvi SMD, Ahmad K, Baig MH, Lee EJ, Choi I. 2019. Mechanistic insights into the antimicrobial actions of metallic nanoparticles and their implications for multidrug resistance. IJMS. 20(10):2468.
   Google Scholar
• Shalaby WSW, Blevins WE, Park K. 1991. Gastric retention of enzyme-digestible hydrogels in the canine stomach under fasted and fed conditions: A Preliminary Analysis Using New Analytical Techniques. In: Polymeric drugs and drug delivery systems. Washington (DC): American Chemical Society; p. 237–248.
   Google Scholar
• Sharaf SMA, Abbas HS, Ismaeil TAM. 2019. Characterization of spirugenic iron oxide nanoparticles and their antibacterial activity against multidrug-resistant Helicobacter pylori. Egypt J Phycol. 20(1):1–28.
   Google Scholar
• Silva ÉL, Carvalho JF, Pontes TRF, Oliveira EE, Francelino BL, Medeiros AC, do Egito EST, Araujo JH, Carriço AS. 2009. Development of a magnetic system for the treatment of Helicobacter pylori infections. J Magn Magn Mater. 321(10):1566–1570.
   Web of Science ®Google Scholar
• Singh BN, Kim KH. 2000. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 63(3):235–259.
   PubMed Web of Science ®Google Scholar
• Singh Y, Meher JG, Raval K, Khan FA, Chaurasia M, Jain NK, Chourasia MK. 2017. Nanoemulsion: Concepts, development and applications in drug delivery. J Control Release. 252:28–49.
   PubMed Web of Science ®Google Scholar
• Singhai N, Maurya R, Ramteke S, Jain S. 2019. Formulation and evaluation of amoxicillin-trihydrate, metronidazole and famotidine loaded mucoadhesive gastro-retentive films. Int J App Pharm. 11(5):131–142.
   Google Scholar
• Spósito L, Oda FB, Vieira JH, Carvalho FA, Dos Santos Ramos MA, de Castro RC, Crevelin EJ, Crotti AEM, Santos AG, da Silva PB, et al. 2019. In vitro and in vivo anti-Helicobacter pylori activity of Casearia sylvestris leaf derivatives. J Ethnopharmacol. 233:1–12.
   PubMed Web of Science ®Google Scholar
• Sreelakshmy V, Deepa MK, Mridula P. 2016. Green synthesis of silver nanoparticles from Glycyrrhiza glabra root extract for the treatment of gastric ulcer. J Dev Drugs. 5(152):2.
   Google Scholar
• Šterbenc A, Jarc E, Poljak M, Homan M. 2019. Helicobacter pylori virulence genes. World J Gastroenterol. 25(33):4870–4884.
   PubMed Web of Science ®Google Scholar
• Streubel A, Siepmann J, Bodmeier R. 2002. Floating microparticles based on low density foam powder. Int J Pharm. 241(2):279–292.
   PubMed Web of Science ®Google Scholar
• Streubel A, Siepmann J, Bodmeier R. 2006. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr Opin Pharmacol. 6(5):501–508.
   PubMed Web of Science ®Google Scholar
• Sutton P, Boag JM. 2019. Status of vaccine research and development for Helicobacter pylori. Vaccine. 37(50):7295–7299.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Moayyedi P. 2013. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol. 10(3):168–174.
   PubMed Web of Science ®Google Scholar
• Swain S, Sahu P, Beg S, Babu S. 2016. Nanoparticles for cancer targeting: current and future directions. Curr Drug Deliv. 13(8):1290–1302.
   PubMed Web of Science ®Google Scholar
• Thamphiwatana S, Gao W, Obonyo M, Zhang L. 2014. In vivo treatment of Helicobacter pylori infection with liposomal linolenic acid reduces colonization and ameliorates inflammation. Proc Natl Acad Sci U S A. 111(49):17600–17605.
   PubMed Web of Science ®Google Scholar
• Thombre NA, Gide PS. 2016. Floating-bioadhesive gastroretentive Caesalpinia pulcherrima-based beads of amoxicillin trihydrate for Helicobacter pylori eradication. Drug Deliv. 23(2):405–419.
   PubMed Web of Science ®Google Scholar
• Timmermans J, Moës AJ. 1994. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy. J Pharm Sci. 83(1):18–24.
   PubMed Web of Science ®Google Scholar
• Tran LTC, Gueutin C, Frebourg G, Burucoa C, Faivre V. 2017. Erythromycin encapsulation in nanoemulsion-based delivery systems for treatment of Helicobacter pylori infection: Protection and synergy. Biochem Biophys Res Commun. 493(1):146–151.
   PubMed Web of Science ®Google Scholar
• Tripathi J, Thapa P, Maharjan R, Jeong SH. 2019. Current state and future perspectives on gastroretentive drug delivery systems. Pharmaceutics. 11(4):193.
   PubMed Web of Science ®Google Scholar
• Umamaheshwari RB, Jain NK. 2003. Receptor mediated targeting of lectin conjugated gliadin nanoparticles in the treatment of Helicobacter pylori. J Drug Target. 11(7):415–424.
   PubMed Web of Science ®Google Scholar
• Vergnaud J-M. 1993. Controlled drug release of oral dosage forms. Boca Raton: CRC Press.
   Google Scholar
• Warren JR, Marshall B. 1983. Unidentified curved Bacilli on gastric epithelium in active chronic gastritis. Lancet. 321(8336):1273–1275.
   Google Scholar
• Weir E, Lawlor A, Whelan A, Regan F. 2008. The use of nanoparticles in anti-microbial materials and their characterization. Analyst. 133(7):835–845.
   PubMed Web of Science ®Google Scholar
• Wessler S, Krisch LM, Elmer DP, Aberger F. 2017. From inflammation to gastric cancer - the importance of Hedgehog/GLI signaling in Helicobacter pylori-induced chronic inflammatory and neoplastic diseases. Cell Commun Signal. 15(1):15–13.
   PubMed Web of Science ®Google Scholar
• Yadav HKS, Almokdad AA, Sumia IM, Debe MS. 2019. Chapter 17 - polymer-based nanomaterials for drug-delivery carriers. In Nanocarriers for drug delivery. Elsevier Inc.
   Google Scholar
• Yang JC, Lu CW, Lin CJ. 2014. Treatment of Helicobacter pylori infection: current status and future concepts. World J Gastroenterol. 20(18):5283–5293.
   PubMed Web of Science ®Google Scholar
• Yuan XY, Wang Y, Wang MY. 2018. The type IV secretion system in Helicobacter pylori. Future Microbiol. 13(9):1041–1054.
   PubMed Web of Science ®Google Scholar
• Zhang F, Chen C, Hu J, Su R, Zhang J, Han Z, Chen H, Li Y. 2019. Molecular mechanism of Helicobacter pylori – induced autophagy in gastric cancer. Oncol Lett. 18:6221–6227.
   PubMed Web of Science ®Google Scholar
• Zhang M. 2015. High antibiotic resistance rate: a difficult issue for Helicobacter pylori eradication treatment. World J Gastroenterol. 21(48):13432–13437.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Song C, Wang K, Li D, Yang Y, Liu D, Wang L, Zhou N, Xie Y. 2020. Prevalence of Helicobacter pylori babA, oipA, sabA, and homB genes in isolates from Chinese patients with different gastroduodenal diseases. Med Microbiol Immunol. 209(5):565–577.
   PubMed Web of Science ®Google Scholar
• Zhao S, Lv Y, Zhang J-B, Wang B, Lv G-J, Ma X-J. 2014. Gastroretentive drug delivery systems for the treatment of Helicobacter pylori. World J Gastroenterol. 20(28):9321–9329.
   PubMed Web of Science ®Google Scholar